Abstract
Background
Immunotherapy is a rapidly emerging approach to cancer therapy that focuses on empowering the immune system by countering the mechanisms whereby cancer cells frequently evade immunosurveillance and negate anticancer immune responses. However, there are major challenges to successful implementation of immunotherapy approaches in cancer treatment, mainly due to a lack of targetability and inefficient delivery of immunotherapeutics at the target site.
Area covered
The current review focuses on various anticancer immunotherapy approaches that have recently been investigated and employed, as well as on nanoparticle-based delivery techniques for immunotherapeutics that are being implemented as strategic approaches to overcome the limitations of cancer immunotherapy.
Expert opinion
Nanoparticle-based delivery techniques for immunotherapeutics have shown immense potential in effective targeting and efficient delivery of these agents at target sites, resulting in effective repression of the immune-evasive mechanisms employed by cancer cells, thereby significantly inducing immune-mediated cancer cell killing and inhibition of tumor proliferation and metastasis. Further understanding of cancer immunology and investigations into enhancing the specificity and targetability of nanoparticle delivery devices can lead to clinical success of nanoparticle-based immunotherapy approaches in cancer treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Angell TE, Lechner MG, Jang JK, LoPresti JS, Epstein AL (2014) MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin Cancer Res 20(23):6034–6044. https://doi.org/10.1158/1078-0432.Ccr-14-0879
Berraondo P, Sanmamed MF, Ochoa MC et al (2019) Cytokines in clinical cancer immunotherapy. Br J Cancer 120(1):6–15. https://doi.org/10.1038/s41416-018-0328-y
Bladergroen BA, Meijer CJ, ten Berge RL et al (2002) Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system? Blood 99(1):232–237. https://doi.org/10.1182/blood.v99.1.232
Boyiadzis MM, Dhodapkar MV, Brentjens RJ et al (2018) Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer 6(1):137. https://doi.org/10.1186/s40425-018-0460-5
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492
Cervantes-Villagrana RD, Albores-García D, Cervantes-Villagrana AR, García-Acevez SJ (2020) Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies. Signal Transduct Target Ther 5(1):99. https://doi.org/10.1038/s41392-020-0205-z
Cheever MA, Higano CS (2011) PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 17(11):3520–3526. https://doi.org/10.1158/1078-0432.Ccr-10-3126
Chen H, Fan Y, Hao X et al (2020a) Adoptive cellular immunotherapy of tumors via effective CpG delivery to dendritic cells using dendrimer-entrapped gold nanoparticles as a gene vector. J Mater Chem B 8(23):5052–5063. https://doi.org/10.1039/d0tb00678e
Chen XJ, Zhang XQ, Tang MX, Liu Q, Zhou G (2020b) Anti-PD-L1-modified and ATRA-loaded nanoparticles for immuno-treatment of oral dysplasia and oral squamous cell carcinoma. Nanomedicine (Lond) 15(10):951–968. https://doi.org/10.2217/nnm-2019-0397
Cho H, Lai TC, Tomoda K, Kwon GS (2015) Polymeric micelles for multi-drug delivery in cancer. AAPS PharmSciTech 16(1):10–20. https://doi.org/10.1208/s12249-014-0251-3
Choi B, Jung H, Yu B, Choi H, Lee J, Kim DH (2019) Sequential MR image-guided local immune checkpoint blockade cancer immunotherapy using ferumoxytol capped ultralarge pore mesoporous silica carriers after standard chemotherapy. Small 15(52):e1904378. https://doi.org/10.1002/smll.201904378
Dai L, Li X, Yao M et al (2020) Programmable prodrug micelle with size-shrinkage and charge-reversal for chemotherapy-improved IDO immunotherapy. Biomaterials 241:119901. https://doi.org/10.1016/j.biomaterials.2020.119901
Dang Y, Guan J (2020) Nanoparticle-based drug delivery systems for cancer therapy. Smart Mater Med 1:10–19. https://doi.org/10.1016/j.smaim.2020.04.001
De Cicco P, Ercolano G, Ianaro A (2020) The new era of cancer immunotherapy: targeting myeloid-derived suppressor cells to overcome immune evasion. Front Immunol 11:1680. https://doi.org/10.3389/fimmu.2020.01680
Dey A, Manna S, Kumar S, Chattopadhyay S, Saha B, Roy S (2020) Immunostimulatory effect of chitosan conjugated green copper oxide nanoparticles in tumor immunotherapy. Cytokine 127:154958. https://doi.org/10.1016/j.cyto.2019.154958
Fang M, Yuan J, Peng C, Li Y (2014) Collagen as a double-edged sword in tumor progression. Tumour Biol 35(4):2871–2882. https://doi.org/10.1007/s13277-013-1511-7
Fellner C (2012) Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. P T 37(9):503–530
Festino L, Botti G, Lorigan P et al (2016) Cancer treatment with anti-PD-1/PD-L1 agents: is PD-L1 expression a biomarker for patient selection? Drugs 76(9):925–945. https://doi.org/10.1007/s40265-016-0588-x
Gao A, Hu X-l, Saeed M, Chen B-f, Li Y-p, Yu H-j (2019) Overview of recent advances in liposomal nanoparticle-based cancer immunotherapy. Acta Pharmacol Sin 40(9):1129–1137. https://doi.org/10.1038/s41401-019-0281-1
Gravbrot N, Gilbert-Gard K, Mehta P et al (2019) Therapeutic monoclonal antibodies targeting immune checkpoints for the treatment of solid tumors. Antibodies (Basel). https://doi.org/10.3390/antib8040051
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. https://doi.org/10.1016/j.cell.2011.02.013
Hjálmsdóttir Á, Bühler C, Vonwil V et al (2016) Cytosolic delivery of liposomal vaccines by means of the concomitant photosensitization of phagosomes. Mol Pharm 13(2):320–329. https://doi.org/10.1021/acs.molpharmaceut.5b00394
Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723. https://doi.org/10.1056/NEJMoa1003466
Hollingsworth RE, Jansen K (2019) Turning the corner on therapeutic cancer vaccines. NPJ Vaccines 4:7. https://doi.org/10.1038/s41541-019-0103-y
Huang Z, Wei G, Zeng Z et al (2019) Enhanced cancer therapy through synergetic photodynamic/immune checkpoint blockade mediated by a liposomal conjugate comprised of porphyrin and IDO inhibitor. Theranostics 9(19):5542–5557. https://doi.org/10.7150/thno.35343
Huang KW, Hsu FF, Qiu JT et al (2020) Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer. Sci Adv 6(3):5032. https://doi.org/10.1126/sciadv.aax5032
Kedar U, Phutane P, Shidhaye S, Kadam V (2010) Advances in polymeric micelles for drug delivery and tumor targeting. Nanomed Nanotechnol Biol Med 6(6):714–729. https://doi.org/10.1016/j.nano.2010.05.005
Kruger S, Ilmer M, Kobold S et al (2019) Advances in cancer immunotherapy 2019—latest trends. J Exp Clin Cancer Res 38(1):268. https://doi.org/10.1186/s13046-019-1266-0
Kuczek DE, Larsen AMH, Thorseth ML et al (2019) Collagen density regulates the activity of tumor-infiltrating T cells. J Immunother Cancer 7(1):68. https://doi.org/10.1186/s40425-019-0556-6
Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA (2014) Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014:149185. https://doi.org/10.1155/2014/149185
Lee A, Duggan S, Deeks ED (2020) Cemiplimab: a review in advanced cutaneous squamous cell carcinoma. Drugs 80(8):813–819. https://doi.org/10.1007/s40265-020-01302-2
Li A, Zhao J, Fu J, Cai J, Zhang P (2019a) Recent advances of biomimetic nano-systems in the diagnosis and treatment of tumor. Asian J Pharm Sci. https://doi.org/10.1016/j.ajps.2019.08.001
Li Y, Ayala-Orozco C, Rauta PR, Krishnan S (2019b) The application of nanotechnology in enhancing immunotherapy for cancer treatment: current effects and perspective. Nanoscale 11(37):17157–17178. https://doi.org/10.1039/c9nr05371a
Lim S, Park J, Shim MK et al (2019) Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy. Theranostics 9(25):7906–7923. https://doi.org/10.7150/thno.38425
Lin Y, Xu J, Lan H (2019) Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J Hematol Oncol 12(1):76. https://doi.org/10.1186/s13045-019-0760-3
Liu Q, Zhou Y, Li M et al (2019a) Polyethylenimine hybrid thin-shell hollow mesoporous silica nanoparticles as vaccine self-adjuvants for cancer immunotherapy. ACS Appl Mater Interfaces 11(51):47798–47809. https://doi.org/10.1021/acsami.9b19446
Liu Y, Chen XG, Yang PP, Qiao ZY, Wang H (2019b) Tumor microenvironmental ph and enzyme dual responsive polymer-liposomes for synergistic treatment of cancer immuno-chemotherapy. Biomacromol 20(2):882–892. https://doi.org/10.1021/acs.biomac.8b01510
Lu J, Liu X, Liao YP et al (2018) Breast cancer chemo-immunotherapy through liposomal delivery of an immunogenic cell death stimulus plus interference in the IDO-1 pathway. ACS Nano 12(11):11041–11061. https://doi.org/10.1021/acsnano.8b05189
Lu KL, Wu MY, Wang CH et al (2019) The role of immune checkpoint receptors in regulating immune reactivity in lupus. Cells. https://doi.org/10.3390/cells8101213
Marhelava K, Pilch Z, Bajor M, Graczyk-Jarzynka A, Zagozdzon R (2019) Targeting negative and positive immune checkpoints with monoclonal antibodies in therapy of cancer. Cancers (Basel). https://doi.org/10.3390/cancers11111756
Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S, Lou Y (2018) Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol 11(1):39. https://doi.org/10.1186/s13045-018-0582-8
Marquez-Rodas I, Aznar MA, Calles A, Melero I (2019) For whom the cell tolls? Intratumoral treatment links innate and adaptive immunity. Clin Cancer Res 25(4):1127–1129. https://doi.org/10.1158/1078-0432.Ccr-18-2690
McCoy KD, Le Gros G (1999) The role of CTLA-4 in the regulation of T cell immune responses. Immunol Cell Biol 77(1):1–10. https://doi.org/10.1046/j.1440-1711.1999.00795.x
Mitsuiki N, Schwab C, Grimbacher B (2019) What did we learn from CTLA-4 insufficiency on the human immune system? Immunol Rev 287(1):33–49. https://doi.org/10.1111/imr.12721
Miyabe H, Hyodo M, Nakamura T, Sato Y, Hayakawa Y, Harashima H (2014) A new adjuvant delivery system “cyclic di-GMP/YSK05 liposome” for cancer immunotherapy. J Control Release 184:20–27. https://doi.org/10.1016/j.jconrel.2014.04.004
Moura LIF, Malfanti A, Peres C et al (2019) Functionalized branched polymers: promising immunomodulatory tools for the treatment of cancer and immune disorders. Mater Horiz 6(10):1956–1973. https://doi.org/10.1039/C9MH00628A
Mu W, Chu Q, Liu Y, Zhang N (2020) A review on nano-based drug delivery system for cancer chemoimmunotherapy. Nano-Micro Lett 12(1):142. https://doi.org/10.1007/s40820-020-00482-6
Ning YM, Suzman D, Maher VE et al (2017) FDA Approval summary: atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum-containing chemotherapy. Oncologist 22(6):743–749. https://doi.org/10.1634/theoncologist.2017-0087
Nossal GJ (1994) Negative selection of lymphocytes. Cell 76(2):229–239. https://doi.org/10.1016/0092-8674(94)90331-x
Ou W, Byeon JH, Soe ZC et al (2019) Tailored black phosphorus for erythrocyte membrane nanocloaking with interleukin-1α siRNA and paclitaxel for targeted, durable, and mild combination cancer therapy. Theranostics 9(23):6780–6796. https://doi.org/10.7150/thno.37123
Park KS, Xu C, Sun X, Louttit C, Moon JJ (2020) Improving STING agonist delivery for cancer immunotherapy using biodegradable mesoporous silica nanoparticles. Adv Therap 3(10):2000130. https://doi.org/10.1002/adtp.202000130
Qin W, Hu L, Zhang X et al (2019) The diverse function of PD-1/PD-L pathway beyond cancer. Front Immunol 10:2298. https://doi.org/10.3389/fimmu.2019.02298
Raedler LA (2015a) Keytruda (Pembrolizumab): first PD-1 inhibitor approved for previously treated unresectable or metastatic melanoma. Am Health Drug Benefits 8:96–100
Raedler LA (2015b) Opdivo (Nivolumab): second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma. Am Health Drug Benefits 8:180–183
Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359(6382):1350–1355. https://doi.org/10.1126/science.aar4060
Riella LV, Paterson AM, Sharpe AH, Chandraker A (2012) Role of the PD-1 pathway in the immune response. Am J Transplant 12(10):2575–2587. https://doi.org/10.1111/j.1600-6143.2012.04224.x
Robert C (2020) A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun 11(1):3801. https://doi.org/10.1038/s41467-020-17670-y
Romo-Tena J, Gómez-Martín D, Alcocer-Varela J (2013) CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance. Autoimmun Rev 12(12):1171–1176. https://doi.org/10.1016/j.autrev.2013.07.002
Rosenblum D, Joshi N, Tao W, Karp JM, Peer D (2018) Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun 9(1):1410. https://doi.org/10.1038/s41467-018-03705-y
Rueda F, Eich C, Cordobilla B et al (2017) Effect of TLR ligands co-encapsulated with multiepitopic antigen in nanoliposomes targeted to human DCs via Fc receptor for cancer vaccines. Immunobiology 222(11):989–997. https://doi.org/10.1016/j.imbio.2017.06.002
Salmaninejad A, Valilou SF, Shabgah AG et al (2019) PD-1/PD-L1 pathway: basic biology and role in cancer immunotherapy. J Cell Physiol 234(10):16824–16837. https://doi.org/10.1002/jcp.28358
Shi Z, Zhou Y, Fan T, Lin Y, Zhang H, Mei L (2020) Inorganic nano-carriers based smart drug delivery systems for tumor therapy. Smart Mater Med 1:32–47. https://doi.org/10.1016/j.smaim.2020.05.002
Siegel RL, Miller KD, Jemal A (2020) Cancer statistics. CA Cancer J Clin 70(1):7–30. https://doi.org/10.3322/caac.21590
Siegler EL, Kim YJ, Chen X et al (2017) Combination cancer therapy using chimeric antigen receptor-engineered natural killer cells as drug carriers. Mol Ther 25(12):2607–2619. https://doi.org/10.1016/j.ymthe.2017.08.010
Siriwon N, Kim YJ, Siegler E et al (2018) CAR-T cells surface-engineered with drug-encapsulated nanoparticles can ameliorate intratumoral T-cell hypofunction. Cancer Immunol Res 6(7):812–824. https://doi.org/10.1158/2326-6066.Cir-17-0502
Su Z, Xiao Z, Wang Y et al (2020) Codelivery of anti-PD-1 antibody and paclitaxel with matrix metalloproteinase and pH dual-sensitive micelles for enhanced tumor chemoimmunotherapy. Small 16(7):e1906832. https://doi.org/10.1002/smll.201906832
Thomas DA, Massagué J (2005) TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8(5):369–380. https://doi.org/10.1016/j.ccr.2005.10.012
Topalian Suzanne L, Drake Charles G, Pardoll Drew M (2015) Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27(4):450–461. https://doi.org/10.1016/j.ccell.2015.03.001
Toy R, Roy K (2016) Engineering nanoparticles to overcome barriers to immunotherapy. Bioeng Transl Med 1(1):47–62. https://doi.org/10.1002/btm2.10005
Varypataki EM, van der Maaden K, Bouwstra J, Ossendorp F, Jiskoot W (2015) Cationic liposomes loaded with a synthetic long peptide and poly(I:C): a defined adjuvanted vaccine for induction of antigen-specific T cell cytotoxicity. AAPS J 17(1):216–226. https://doi.org/10.1208/s12248-014-9686-4
Voena C, Chiarle R (2016) Advances in cancer immunology and cancer immunotherapy. Discov Med 21(114):125–133
Waldman AD, Fritz JM, Lenardo MJ (2020) A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 20(11):651–668. https://doi.org/10.1038/s41577-020-0306-5
Wan S, Zhang B, Li S, He B, Pu Y (2020) Combination of PEG-decorated black phosphorus nanosheets and immunoadjuvant for photoimmunotherapy of melanoma. J Mater Chem B 8(14):2805–2813. https://doi.org/10.1039/D0TB00434K
Wang L, Wang M, Zhou B et al (2019a) PEGylated reduced-graphene oxide hybridized with Fe3O4 nanoparticles for cancer photothermal-immunotherapy. J Mater Chem B 7(46):7406–7414. https://doi.org/10.1039/C9TB00630C
Wang Y, Kim TH, Fouladdel S et al (2019b) PD-L1 expression in circulating tumor cells increases during radio(chemo)therapy and indicates poor prognosis in non-small cell lung cancer. Sci Rep 9(1):566. https://doi.org/10.1038/s41598-018-36096-7
Wei J, Long Y, Guo R et al (2019) Multifunctional polymeric micelle-based chemo-immunotherapy with immune checkpoint blockade for efficient treatment of orthotopic and metastatic breast cancer. Acta Pharm Sin B 9(4):819–831. https://doi.org/10.1016/j.apsb.2019.01.018
Wu X, Gu Z, Chen Y et al (2019) Application of PD-1 blockade in cancer immunotherapy. Comput Struct Biotechnol J 17:661–674. https://doi.org/10.1016/j.csbj.2019.03.006
Xia C, Yin S, Xu S et al (2019) Low molecular weight heparin-coated and dendrimer-based core-shell nanoplatform with enhanced immune activation and multiple anti-metastatic effects for melanoma treatment. Theranostics 9(2):337–354. https://doi.org/10.7150/thno.29026
Xu C, Hong H, Lee Y et al (2020a) Efficient lymph node-targeted delivery of personalized cancer vaccines with reactive oxygen species-inducing reduced graphene oxide nanosheets. ACS Nano 14(10):13268–13278. https://doi.org/10.1021/acsnano.0c05062
Xu D, Liu J, Wang Y, Jian Y, Wu W, Lv R (2020b) Black phosphorus nanosheet with high thermal conversion efficiency for photodynamic/photothermal/immunotherapy. ACS Biomater Sci Eng 6(9):4940–4948. https://doi.org/10.1021/acsbiomaterials.0c00984
Yan WL, Shen KY, Tien CY, Chen YA, Liu SJ (2017) Recent progress in GM-CSF-based cancer immunotherapy. Immunotherapy 9(4):347–360. https://doi.org/10.2217/imt-2016-0141
Yan M, Liu Y, Zhu X et al (2019) Nanoscale reduced graphene oxide-mediated photothermal therapy together with IDO inhibition and PD-L1 blockade synergistically promote antitumor immunity. ACS Appl Mater Interfaces 11(2):1876–1885. https://doi.org/10.1021/acsami.8b18751
Yang H (2016) Targeted nanosystems: advances in targeted dendrimers for cancer therapy. Nanomedicine 12(2):309–316. https://doi.org/10.1016/j.nano.2015.11.012
Yu W, Hua Y, Qiu H et al (2020) PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer. Cell Death Dis 11(7):506. https://doi.org/10.1038/s41419-020-2701-z
Yuba E, Harada A, Sakanishi Y, Watarai S, Kono K (2013) A liposome-based antigen delivery system using pH-sensitive fusogenic polymers for cancer immunotherapy. Biomaterials 34(12):3042–3052. https://doi.org/10.1016/j.biomaterials.2012.12.031
Yuba E, Tajima N, Yoshizaki Y, Harada A, Hayashi H, Kono K (2014) Dextran derivative-based pH-sensitive liposomes for cancer immunotherapy. Biomaterials 35(9):3091–3101. https://doi.org/10.1016/j.biomaterials.2013.12.024
Zaenker P, Gray ES, Ziman MR (2016) Autoantibody production in cancer—the humoral immune response toward autologous antigens in cancer patients. Autoimmun Rev 15(5):477–483. https://doi.org/10.1016/j.autrev.2016.01.017
Zhang Y, Zhang Z (2020) The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 17(8):807–821. https://doi.org/10.1038/s41423-020-0488-6
Zhang Y, Li N, Suh H, Irvine DJ (2018) Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity. Nat Commun 9(1):6. https://doi.org/10.1038/s41467-017-02251-3
Zhang D, Wu T, Qin X et al (2019) Intracellularly generated immunological gold nanoparticles for combinatorial photothermal therapy and immunotherapy against tumor. Nano Lett 19(9):6635–6646. https://doi.org/10.1021/acs.nanolett.9b02903
Zhang M, Du Y, Wang S, Chen B (2020) A review of biomimetic nanoparticle drug delivery systems based on cell membranes. Drug Des Dev Ther 14:5495–5503. https://doi.org/10.2147/dddt.S282368
Zhao Z, Zheng L, Chen W, Weng W, Song J, Ji J (2019) Delivery strategies of cancer immunotherapy: recent advances and future perspectives. J Hematol Oncol 12(1):126. https://doi.org/10.1186/s13045-019-0817-3
Zhao P, Wang M, Chen M et al (2020) Programming cell pyroptosis with biomimetic nanoparticles for solid tumor immunotherapy. Biomaterials 254:120142. https://doi.org/10.1016/j.biomaterials.2020.120142
Zhou S, Huang Y, Chen Y et al (2020) Engineering ApoE3-incorporated biomimetic nanoparticle for efficient vaccine delivery to dendritic cells via macropinocytosis to enhance cancer immunotherapy. Biomaterials 235:119795. https://doi.org/10.1016/j.biomaterials.2020.119795
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
All authors (B. Gupta and J.O. Kim) declare that they have no conflict of interest.
Statement of human and animal rights
The article does not contain any studies with human and/or animal subjects by any of the authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Gupta, B., Kim, J.O. Recent progress in cancer immunotherapy approaches based on nanoparticle delivery devices. J. Pharm. Investig. 51, 399–412 (2021). https://doi.org/10.1007/s40005-021-00527-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40005-021-00527-x